<DOC>
	<DOC>NCT01110629</DOC>
	<brief_summary>The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.</brief_summary>
	<brief_title>Study in Chronic Kidney Disease (CKD) Not on Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Male and female patients aged 20 years or above at the time of informed consent Chronic Kidney Disease patients with Epidermal growth factor receptor (eGFR) under 60 ml/min/1.73m2 (stage 3, 4 and 5) who have not been on dialysis Patients who had been in the care of a physician for Chronic Kidney Disease for &gt;2 months and was not expected to begin dialysis for at least 4 months Patients with serum phosphate levels 5.6 mg/dL to 11.0 mg/dL at Week 4 (Visit 1) or Week 2 (Visit 2) Patients with hypocalcemia or hypercalcemia (corrected serum calcium level of &lt; 7.0 mg/dL or &gt;/ 11.0 mg/dL) at Week 2 (Visit 2). Significant renal impairments Had acute renal failure within 3 months of Runin period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Chronic kidney disease not on dialysis</keyword>
	<keyword>Lanthanum carbonate</keyword>
</DOC>